DNLI Schedule 13G/A filing by T. Rowe Price Investment Management
T. Rowe Price Investment Management reported beneficial ownership of 16.2M shares, representing 12% of Denali Therapeutics Inc. in this filing.
Voting and dispositive power reported in the filing
These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.
How the reported position changed
This compares the current filing with the previous tracked Schedule 13 filing from the same reporting CIK for DNLI. A change between filings does not by itself establish when shares were bought or sold.
| Previous filing | This filing | |
|---|---|---|
| Reported shares | 8.5M | 16.2M |
| Reported ownership | 12% | 12% |
Price dates alongside the ownership filing
Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.
Original filing and accession
Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.
- Reporting filer
- T. Rowe Price Investment Management
- CIK
- CIK0001897612
- Accession
- 0001897612-26-000525
- Form
- Schedule 13G/A